Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Burroughs Wellcome’s Flolan

Executive Summary

Clinical study in patients with severe end-stage congestive heart failure discontinued due to higher rate of mortality in Flolan (epoprostenol) treated group compared to the standard therapy, firm reports June 21. In the trial of 450 patients, which began 18 months ago, quality of life and exercise tolerance also declined for the Flolan-treated group. The company said that the results in congestive heart failure do not affect the development of Flolan for primary pulmonary hypertension, an orphan indication for which Burroughs Wellcome is planning to file an NDA in 1993 ("The Pink Sheet" May 10, p. 14).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022839

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel